Think Locally, Source Globally: Are Your Product Region-Fixed or Trans-Continental?

18 Jan 2023
Supply Chain and Technical Operations Track
CSafe Global
Fujifilm Irvine Scientific

11:00am Chair Introduction

Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics


11:05am Presentation: Cell and Gene Therapy: These Identifiers Are Getting Out of Hand

  • How it started: a brief overview of how we got here and why there are so many different Cell and Gene Therapy product identifiers
  • How’s it going: ISBT-128 ST-028 (Chain of Identity Identifier) and benefits to clinical site & patient
  • Next Steps

Beth Gardner, Senior Director, Patient Supply, Beam Therapeutics


11:20am Presentation: Key Considerations When Choosing Recombinant Proteins for Cell and Gene Therapy Applications

  • Interleukins (ILs): The role they play in the regulation of adaptive cellular response
  • Critical factors when selecting a supplier for your recombinant proteins
  • Developing recombinant growth factors and cytokines for cell-based therapies
  • Achieving optimal results through a scientifically-driven selection of products
  • Why a close partnership with your supplier can accelerate the development process to therapy 

Robert Newman, Chief Scientific Officer, FujiFilm Irvine Scientific


11:35am Presentation: TBC

Jeff Liter, Chief Executive Officer, Luminary Therapeutics


11:50am Presentation:TBA

Senior Representative, CSafe


12:05pm Closing Panel with Q&A

With all session participants Joined by: 

Lisa McClain-Moss, Vice President of Manufacturing, Longeveron


Beth Gardner
Senior Director, Patient Supply
Beam Therapeutics
Jeff Liter
President and Chief Executive Officer
Luminary Therapeutics
Lisa McClain-Moss
Vice President, Manufacturing
Robert Newman
Chief Scientific Officer
Fujifilm Irvine Scientific
Troels Jordansen
Chief Executive Officer